Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

Annals of Oncology

Volumn 7, Issue 6, 1996, Pages 593-600

  Glimelius, B ^a   Hoffman, K ^a   Sjoden P O ^a   Jacobsson, G ^a   Sellstrom H ^b   Enander, L K ^c   Linne T ^c   Svensson, C ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Sjukhuset   (Sweden)

^c Centralsjukhuset ^*  (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biliary cancer; Chemotherapy; Palliation; Pancreatic cancer; Randomized study

Indexed keywords

ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BILE DUCT CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PALLIATIVE THERAPY; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL; VOMITING;

EID: 0029816590     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010676     Document Type: Article

References (46)

1. Zimmerman S, Smith F, Schein P. Chemotherapy of pancreatic carcinoma. Cancer 1981; 47: 1724-8.
2. Mallinson CN, Rake MO, Cocking JB et al. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomized, multicentre trial. BMJ 1980; 281: 1589-91.
3. Andersen JR, Friis-Moller A, Hancke S et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand J Gastroenterol 1981; 16: 973-5.
4. Frey C, Twomey P, Keehn R et al. Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981; 47: 27-31.
5. Andren-Sandberg A, Holmberg JT, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU. Scand J Gastroenterol 1983; 18: 609-12.
6. Lionetto R, Pugliese V, Bruzzi P et al. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995; 6: 882-7.
7. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5.
8. Tophman C, Glees J, Rawson NSB et al. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer 1991; 64: 179-81.
9. Kelsen D, Hudis C, Niedzwiecki D et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68: 965-9.
10. Oster MW, Gray R, Panasci L et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57: 29-33.
11. deCaprio J, Mayer R, Gonin R et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991; 9: 2128-3.
12. Crown J, Casper E, Botet J et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-6.
13. Asbury RF, Cnaan A, Johnson L et al. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer. Am J Clin Oncol 1994; 17(2): 166-9.
14. Sternberg CN, Magill GB, Cheng EW et al. Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 1988; 11: 172-3.
15. Cullinan S, Moertel CG, Wieand HS et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 1990; 65:2207-12.
16. Moore M. Improvements in survival and clinical benefit with the use of Gemcitabine (GEM) as first-line therapy for advanced pancreatic cancer: A randomized trial. Proc ECCO 1995; 8: 547.
17. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2 (Suppl 11): 1245-8.
18. Rougier P, Fandi A, Ducreux M et al. Demonstrated efficiency of 5-fluorouracil (5-FU) continuous infusion (CI) and cisplatin (P) in patients with advanced biliary tract carcinoma. Proc Am Soc Clin Oncol, 1995:498.
19. Ellis PA, Norman A, Hill A et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer, 1995; 31 A: 1594-8.
20. Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74.
21. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-41.
22. Care Programme. Caring for cancer patients (in Swedish). Regional Oncological Centre in the Uppsala/Örebro Health Care Region, 1990.
23. Hayward JL, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292-8.
24. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
25. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in clinical trials in oncology. JNCI 1993; 85: 365-76.
26. Glimelius B, Hoffman K, Graf W et al. Quality of life during chemotherapy in symptomatic patients with advanced colorectal cancer. Cancer 1994; 73: 556-62.
27. Consensus Statement. Cytostatic drug treatment in advanced cancer. MFR, Spri, Stockholm, November 1990.
28. Rubens RD, Towlson KE, Ramirez AJ et al. Appropriate chemotherapy for palliating advanced cancer. BMJ 1992; 304: 35-40.
29. Warshaw AL, del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
30. Klapdor R. Perspectives in chemotherapy of pancreatic cancer. Eur J Surg Oncol 1991; 153-66.
31. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300:1458-60.
32. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Sequential methotrexate/5-fluorouracil/leucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 1989; 7: 1437-46.
33. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
34. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-9.
35. Wilke H, Preusser P, Stahl M et al. Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 1991; 29: 83-4.
36. Larsson PA, Carlsson G, Gustavsson B et al. Different intravenous administration techniques for 5-fluorouracil-pharmacokinetic and pharmacodynamic effects. Acta Oncol 1996; 35: 207-13.
37. Hopwood P, Stephens RJ, Machin D for the MRC Lung Cancer Working Party. Approaches to the analysis of quality of life data: Experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 1994; 3: 339-52.
38. Sigurdardöttir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996; 35: 149-59.
39. EORTC, QLQ-C30 Manual, EORTC Study Group on Quality of Life, Brussels, 1995.
40. Glimelius B, Hoffman K, Olafsdottir M et al. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma. A randomized comparison of two regimen. Eur J Cancer Clin Oncol 1989; 25: 829-35.
41. Glimelius B, Graf W, Hoffman K et al. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy: A longitudinal study. Acta Oncol 1992; 31: 645-51.
42. Slevin ML, Plant H, Lynch D et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109-12.
43. Finlay IG, Dunlop R. Quality of life assessment in palliative care. Ann Oncol 1994; 5: 13-8.
44. Glimelius B, Hoffman K, Pâhlman L et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide antigen specific (TPS) measurements. Acta Oncol 1996; 35: 141-8.
45. Kornek G, Schenk T, Raderer M et al. Tissue polypeptide specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 1995; 71: 182-5.
46. Kaplan RM, Bush JW. Health-related quality-of-life measurement for evaluation research and policy analysis. Health Psychol 1982; 1: 61-80.